Glypten Tablet contains Teneligliptin 20mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, Teneligliptin enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. Glypten is prescribed as an adjunct to diet and exercise to improve glycemic parameters in adult patients inadequately controlled on monotherapy or combination therapy with other antidiabetic agents. The medication demonstrates a favorable pharmacokinetic profile with a long half-life, allowing once-daily dosing and improved patient compliance. Clinical studies have shown that Glypten effectively reduces HbA1c and fasting plasma glucose levels with a low risk of hypoglycemia. It is generally well-tolerated, with common adverse effects including mild gastrointestinal disturbances and occasional headache. Caution is advised in patients with renal or hepatic impairment, and dose adjustments may be necessary. Glypten should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose and renal function is recommended during therapy. Glypten Tablet offers an effective and convenient option for optimizing glycemic control in type 2 diabetes management.